SCHEMBL6170690

SCHEMBL6170690

CC(=O)c1[c]ccc(N)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
MAPT P10636 4/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 1/20 0.33
CHEK1 O14757 1/20 0.32
AURKA O14965 1/20 0.32
DAPK3 O43293 1/20 0.32
CSNK1A1 P48729 1/20 0.32
GSK3A P49840 1/20 0.32
LIMK1 P53667 1/20 0.32
IKBKE Q14164 1/20 0.32
MAPK14 Q16539 1/20 0.32
TAOK1 Q7L7X3 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32
DYRK1B Q9Y463 1/20 0.32
GAA P10253 2/20 0.32
PRKCI P41743 1/20 0.32
MEN1 O00255 3/20 0.31
KMT2A Q03164 3/20 0.31
TDP1 Q9NUW8 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27914228 0.83 MAPT (0.34) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL3045441 0.81 KDM4E (0.41) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL11085145 0.79 GAA (0.47) ALDH1A1MAPTRAB9AGAATDP1
SCHEMBL11336223 0.77 CYP2A6 (0.38) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL6152607 0.77 MAPT (0.39) ALDH1A1MAPTNPC1RAB9APRKCI
SCHEMBL22207455 0.77 CA5A (0.38) ALDH1A1MAPTDYRK1BGAAMEN1
SCHEMBL7584988 0.75 MAOB (0.38) ALDH1A1CASP1CYP2C9HPGDALOX15
SCHEMBL7574859 0.75 FSCN1 (0.35) ALDH1A1MAPTNPC1RAB9AMEN1
SCHEMBL9010259 0.75 CES1 (0.35) GAAPOLBTSHR
SCHEMBL5501573 0.74 MEN1 (0.38) ALDH1A1MAPTGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015112739-A9 COMPOUNDS AND METHOD FOR TREATING PARP1-DEFICIENT CANCERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2016-10-20 WO claimed
WO-2015112739-A1 COMPOUNDS AND METHOD FOR TREATING PARP1-DEFICIENT CANCERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2015-07-30 WO claimed
WO-2015112739-A9 COMPOUNDS AND METHOD FOR TREATING PARP1-DEFICIENT CANCERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2016-10-20 WO disclosed
WO-2015112739-A1 COMPOUNDS AND METHOD FOR TREATING PARP1-DEFICIENT CANCERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2015-07-30 WO disclosed
EP-1513809-A1 1-SULFONYL-4-AMINOALKOXY INDOLE DERIVATIVES AS 5-HT6-RECEPTOR MODULATORS FOR THE TREATMENT OF CNS-DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2005-03-16 EP disclosed
WO-2003104193-A1 1-SULFONYL-4-AMINOALKOXY INDOLE DERIVATIVES AS 5-HT6-RECEPTOR MODULATORS FOR THE TREATMENT OF CNS-DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-12-18 WO disclosed
EP-0741319-A1 Photothermographic photosensitive recording material with reduced fog DU PONT DE NEMOURS (DEUTSCHLAND) GMBH (DE) 1996-11-06 EP disclosed
WO-1993015047-A1 AMINO ACID DERIVATIVES AS PAF ANTAGONISTS BRITISH BIO-TECHNOLOGY LIMITED (GB) 1993-08-05 WO disclosed